CELZ Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -3.75%, SMA50 -8.68%, SMA200 -31.81%). The stock’s 14-day RSI is 43.49 (neutral), while the ATR of 0.13 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -72.82% below its high and over 22.34% above its low. Average 10-day trading volume of 370.78 thousand shares is significantly above the 3-month average of 98.71 thousand, indicating heightened recent market interest.

Creative Medical Technology Holdings, Inc. has 2.58 million shares outstanding. The public float is 2.18 million shares, elevated short interest at 4.62% of float. This equals 117.48 thousand shares. The short ratio is 0.81 days. Institutional investors hold 8.15% of the float. Insiders own 1.37%. CREATIVE MEDICAL HEALTH INC. holds 58.66 million shares, Ichim Thomas has 4.53 million shares and Herbst Timothy has 100.00 thousand shares.

Creative Medical Technology Holdings, Inc. generated EPS of -$2.91 over the past year. Five-year average earnings growth is 75.38%. Wall Street analysts project EPS growth of 28.61% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.37. Next year's EPS is expected at -$25.54. Creative Medical Technology Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 08, 2026, missed forecasts by -2.56%. The prior quarter beat by 116.22%. Over the last six quarters, Apple has recorded several small beats. These include 77.78% in March 14, 2025.

Creative Medical Technology Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.02. This means the shares are trading below this model’s fair value.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) closed at $1.68 USD, gaining $0.86 (106.74%) from the previous close of $0.81. The stock is currently mid-range between its 52-week high and low $0.79 and $6.25. With a market capitalization of about $4.32 million, Creative Medical Technology Holdings, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.83). Key stats such as the average daily volume over the past year has been around 99.63 thousand shares, trading with heavier-than-usual volume. Headquartered in Phoenix, AZ, Creative Medical Technology Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Timothy Warbington, the company employs approximately 4 people and listed since November 06, 2015. Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments.

Creative Medical Technology Holdings, Inc. trades at a P/E ratio of -0.41, slightly below the S&P 500 average, with a price-to-sales ratio of 731.27 and a price-to-book ratio of 0.52 suggesting the stock is closer to book value. The P/FCF stands at -0.39, also above market averages.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares are flat 1.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Creative Medical Technology Holdings, Inc. trading at a premium to the broader market with a P/E of -0.41. Our AI forecast model points to short-term strength (12.32% over two weeks), a medium-term fall (-59.27% over three months), and a longer-term loss (-6.2% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Creative Medical Technology Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.32%, with price expected at $0.91 by July 13, 2026, within a range of $0.78 to $1.02 3-Month Outlook: Projected fall of -59.27%, reaching $0.33 by September 25, 2026, with a range of $0.19 to $0.45. 1-Year Outlook: Projected loss of -6.2%, with price at $0.76 by June 29, 2027, within a range of $0.00 to $0.00.